Multiple sclerosis is not a rare disease. Close to 1 million people in the United States have been diagnosed with MS, which is nearly five times the threshold used to define a rare condition. Globally, an estimated 2.8 million people live with the disease. However, certain subtypes of MS and childhood-onset cases are uncommon enough that they approach or meet rare disease criteria.
How Rare Diseases Are Defined
In the United States, the Orphan Drug Act sets a clear line: a disease is considered rare if it affects fewer than 200,000 people in the country. The FDA uses this cutoff to determine which conditions qualify for special incentives in drug development. With roughly 1 million Americans living with MS, the disease exceeds that threshold by a wide margin and does not qualify as rare under federal law.
The National Organization for Rare Disorders (NORD), which maintains a comprehensive database of rare conditions, confirms this directly. Its entry on multiple sclerosis notes that the condition does not meet the U.S. definition of a rare disease, though it acknowledges that some forms of MS may be rare on their own.
How Common MS Actually Is
MS is one of the most prevalent neurological diseases in the world. In the U.S., roughly 4 out of every 1,000 white non-Hispanic people have the condition, about 3 out of every 1,000 Black non-Hispanic people, and approximately 1.5 out of every 1,000 Hispanic or Latino people. These numbers come from a 2019 prevalence study funded by the National MS Society, which nearly doubled previous estimates by using more comprehensive data sources.
Globally, the picture varies dramatically by region. Europe has the highest concentration at about 143 per 100,000 people, while the Western Pacific region has among the lowest at roughly 5 per 100,000. The Americas, northern Europe, and Australia consistently report the highest rates, while equatorial regions in Africa and Southeast Asia report far fewer cases. This geographic pattern has been observed for decades and is linked to a combination of genetic susceptibility, vitamin D exposure, and possibly viral triggers.
Prevalence has also been climbing. The global MS population grew by 30% between 2013 and 2020. That increase likely reflects both a true rise in cases and better detection, since diagnostic tools like MRI have become more widely available and diagnostic criteria have expanded over time.
Subtypes That Are Considered Rare
While MS as a whole is common, not every form of the disease is. Primary progressive MS (PPMS), which causes a steady decline in neurological function from the very beginning rather than the more typical pattern of attacks and remissions, accounts for only 10 to 15% of all MS cases. In the U.S., that translates to roughly 100,000 to 150,000 people, which sits right around the rare disease threshold. This is part of why at least one MS medication has received orphan drug designation from the FDA specifically for progressive forms of the disease.
Pediatric MS is even less common. Children account for only 2 to 5% of all MS cases, putting the U.S. pediatric MS population somewhere in the range of 20,000 to 50,000. That clearly falls below the 200,000 threshold, making childhood-onset MS rare by the formal definition. These children tend to reach permanent disability at a younger age than people diagnosed as adults, and primary progressive MS is extremely uncommon in this group.
Why the Distinction Matters
Whether a disease is classified as rare has real consequences for patients. Rare disease designation unlocks special incentives for pharmaceutical companies to develop treatments, including tax credits, extended market exclusivity, and streamlined approval pathways. Because MS overall is not rare, the broader MS treatment market is large and well served, with more than 20 disease-modifying therapies currently available. That level of pharmaceutical investment simply doesn’t happen for most rare diseases.
For people with rarer subtypes like PPMS, the situation has historically been different. For years, progressive MS had far fewer treatment options than relapsing forms, partly because the smaller patient population made clinical trials harder to run and less commercially attractive. The orphan drug pathway helped bring at least one therapy to market for progressive MS, demonstrating how the rare disease framework can benefit specific patient groups even within a common diagnosis.
If you or someone you know has MS, the practical takeaway is straightforward: the disease is common enough that there is a large research community, a wide range of approved treatments, and extensive support infrastructure. For those with less common subtypes, treatment options are narrower but have been expanding steadily over the past decade.